The SURMOUNT-5 trial found approximately 20.2% average body-weight loss with branded tirzepatide versus 13.7% for branded semaglutide over 72 weeks
300048951-0521 NDC 0065-0800-50 500 mL Single Patient Use BSS PLUS STERILE INTRAOCULAR IRRIGATING SOLUTION (balanced salt solution enriched with bicarbonate, dextrose, and glutathione) After addition of BSS PLUS Part II (20 mL), each mL contains: sodium chloride 7.14 mg, potassium chloride 0.38 mg, calcium chloride dihydrate 0.154 mg, magnesium chloride hexahydrate 0.2 mg, dibasic sodium phosphate 0.42 mg, sodium bicarbonate 2.1 mg, dextrose 0.92 mg, glutathione disulfide (oxidized glutathione) 0.184 mg, hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection
Access and Affordability Challenges: Despite strong clinical benefits, fewer than 1% of eligible US adults are able to afford GLP-1 treatments at current net prices, emphasizing the need for broader coverage and policy solutions
This makes injured tissue more sensitive to circulating growth factors, amplifying the repair signal without requiring additional hormone supplementation
PCAB-accredited 503A compounding pharmacy in Fort Lauderdale, Florida U.S.-licensed 503A compounding pharmacy operating under USP 797 sterile compounding standards Local delivery context and pricing for major Florida metros
Patients and Interventions/Exposure : New users of semaglutide (n= 613) and liraglutide (n=4,144), which are GLP-1 receptor agonists approved for diabetes, and users of buproprion-naltrexone (n= 654), an Federal Drug Administration (FDA)-approved weight loss agent, which served as active comparator